Abstract
<h3>Objective:</h3> We hypothesized that Alzheimer’s disease (AD) biomarkers in cerebrospinal fluid (CSF) would correlate with performance on cognitive and physical therapy assessments following a high volume lumbar puncture (HVLP) in patients with idiopathic normal pressure hydrocephalus <h3>Background:</h3> There is inconsistent data correlating AD biomarkers and iNPH in response to HVLP, as evidenced by mixed results in clinical studies. We sought to identify what relationship, if any, was present between AD biomarkers and iNPH assessments. <h3>Design/Methods:</h3> CSF AD biomarkers (total tau [ttau], phosphorylated tau, β-amyloid, amyloid tau index [ATI]) were analyzed in 166 iNPH patients who underwent HVLP. In additio to biomarkers, we measured changes in cognitive (Montreal Cognitive Assessment, MOCA) and physical therapy assessments (gait scale, time, total gait score) pre- and post-HVLP. <h3>Results:</h3> ATI was significantly negatively correlated with pre- and post-LP gait scale (pre. r=-.206, p<0.05; post. r=-.252, p<0.01) and total gait score (pre. r= −238, p<0.01; post. r= −.271, p<0.05). Ttau was significantly positively correlated with gait total score pre-HVLP (r=.217, p<0.05) and post-HVLP (r=.209, p<0.05). Interestingly, ttau was positively correlated with the length of time it took for patients to complete gait assessment (r=.184, p<0.05) only pre-HVLP. Scores on the pre- and post-HVLP MOCA were positively correlated with ATI (pre r= .451, p<0.01; post r=.421, p<0.01) and negatively correlated with ttau (pre r= −.349, p <0.01, post r= −.377, p<0.01). No correlations existed between β-amyloid, phosphorylated tau, and gait and cognitive assessments. <h3>Conclusions:</h3> Pre- and post-HVLP measures of ttau and ATI were correlated with gait score and time and MOCA performance. These biomarkers associated with AD were correlated with lower MOCA and worse gait scores in iNPH patients. These findings suggest that AD biomarkers may predict worse performance on cognitive and gait assessments in work-up for iNPH. <b>Disclosure:</b> Dr. Acosta has received personal compensation in the range of $500-$4,999 for serving as an Editor, Associate Editor, or Editorial Advisory Board Member for Neurology. The institution of Dr. Acosta has received research support from AbbVie, Biohaven, Roche, NIH. Miss Puckett has nothing to disclose. Anna Pfalzer has nothing to disclose.
Published Version
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.